US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anti-Pandemic Concept

1,352.26

+11.130.83%

Number of Gainers:14

Number of Losers:6

Number of Flat:- -

PE:- -

High:1,355.50

Open:1,341.09

Low:1,341.09

Close:1,341.13

Loading ...

BRIEF-Ibio Inc Enters Exclusive License Agreement With AstralBio

iBio Enters Licensing Agreement for Obesity Treatment

Ibio - Licensing Agreement With Astralbio for Preclinical First-in-Class Antibody Targeting Activin E

THOMSON REUTERS

Ibio Inc - Enters Exclusive License Agreement With Astralbio

THOMSON REUTERS

Johnson & Johnson (NYSE:JNJ) Showcases Paradigm-Shifting Bladder Cancer Trials at AUA 2025

Simply Wall St.

Stocks That Pay Almost 10% Dividend Yields: Dow and Lyondell -- Barrons.com

FOCUS-Trump looking at cutting US drug prices to international levels, sources say

Is Gilead Sciences (GILD) a Cheap NASDAQ Stock to Buy According to Hedge Funds?

Pfizer Inc. (PFE): Among Recent Activist Investor Campaigns

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

FACTBOX-European companies cut jobs as economy slows

BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025

BRIEF-UK's MHRA Says Marstacimab Approved For Patients Aged 12 Years & Above With Haemophilia A Or B

UK's Mhra: Marstacimab Approved to Treat Patients Aged 12 Years and Above (Weighing at Least 35 Kg) With Haemophilia a or B

THOMSON REUTERS

Hutchmed Completes Patient Enrollment in Phase II Gastric Cancer Trial in China

MT Newswires Live

Goldman Sachs Remains a Buy on AstraZeneca (AZN)

EQ Resources Limited Appoints New Director

EQ Resources Strengthens Board with Industry Veteran Appointment

Why the Market Dipped But Novavax (NVAX) Gained Today

Cassava Sciences Chief Medical Officer Kupiec Retires

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4568/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"Anti-Pandemic Concept","latestPrice":1352.2611,"timestamp":1745870399999,"preClose":1341.1263,"halted":0,"volume":111332085,"delay":0,"changeRate":0.008303,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":11.134766,"latestTime":"04-28 16:00:00 EDT","open":1341.0946,"high":1355.5001,"low":1341.0944,"amount":4700789979.16763,"amplitude":0.010742,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745933400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.606724,"peRate":21.80267,"turnoverRate":0.00718,"increases":14,"decrements":6,"flats":0,"marketCap":1116973231290,"floatMarketCap":1097152848382},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1355.5001,"amplitude":0.010742,"preClose":1341.1263,"low":1341.0944,"pbRate":"3.606724","latestPrice":1352.2611,"volume":111332085,"delay":0,"open":1341.0946,"prevYearClose":1274.8187,"prevWeekClose":1341.1263,"prevMonthClose":1427.887,"prevQuarterClose":1427.887,"fiveDayClose":1334.7778,"twentyDayClose":1419.4854,"sixtyDayClose":1364.6776,"secType":"PLATE","market":"US","turnoverRate":0.00718,"peRate":21.80267,"marketCap":1116973231290,"floatMarketCap":1097152848382,"timestamp":1745870399999,"nameCN":"Anti-Pandemic Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":14,"down":6,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529556657","title":"BRIEF-Ibio Inc Enters Exclusive License Agreement With AstralBio","url":"https://stock-news.laohu8.com/highlight/detail?id=2529556657","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529556657?lang=en_us&edition=fundamental","pubTime":"2025-04-23 05:58","pubTimestamp":1745359099,"startTime":"0","endTime":"0","summary":"BRIEF-Ibio Inc Enters Exclusive License Agreement With AstralBioApril 22  - iBio Inc IBIO.O:IBIO INC - ENTERS EXCLUSIVE LICENSE AGREEMENT WITH ASTRALBIOIBIO - LICENSING AGREEMENT WITH ASTRALBIO FOR PRECLINICAL FIRST-IN-CLASS ANTIBODY TARGETING ACTIVIN EIBIO INC - CO TO PAY $750,000 UPFRONT LICENSE FEE TO ASTRALBIOSource text: [ID:n0001420720-25-000020]Further company coverage: IBIO.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nFWN3R02K7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBIO","BK4568"],"gpt_icon":0},{"id":"2529595568","title":"iBio Enters Licensing Agreement for Obesity Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2529595568","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529595568?lang=en_us&edition=fundamental","pubTime":"2025-04-23 04:58","pubTimestamp":1745355481,"startTime":"0","endTime":"0","summary":"An update from Ibio ( ($IBIO) ) is now available. On April 21, 2025, iBio, Inc. entered into an exclusive licensing agreement with AstralBio, Inc. ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ibio-enters-licensing-agreement-for-obesity-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ibio-enters-licensing-agreement-for-obesity-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IBIO","BK4568"],"gpt_icon":0},{"id":"2529955053","title":"Ibio - Licensing Agreement With Astralbio for Preclinical First-in-Class Antibody Targeting Activin E","url":"https://stock-news.laohu8.com/highlight/detail?id=2529955053","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529955053?lang=en_us&edition=fundamental","pubTime":"2025-04-23 04:43","pubTimestamp":1745354630,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nFWN3R02K7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IBIO","BK4568"],"gpt_icon":0},{"id":"2529655770","title":"Ibio Inc - Enters Exclusive License Agreement With Astralbio","url":"https://stock-news.laohu8.com/highlight/detail?id=2529655770","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529655770?lang=en_us&edition=fundamental","pubTime":"2025-04-23 04:43","pubTimestamp":1745354630,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nFWN3R02K7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBIO","BK4139","BK4568"],"gpt_icon":0},{"id":"2529558653","title":"Johnson & Johnson (NYSE:JNJ) Showcases Paradigm-Shifting Bladder Cancer Trials at AUA 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529558653","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529558653?lang=en_us&edition=fundamental","pubTime":"2025-04-23 01:28","pubTimestamp":1745342895,"startTime":"0","endTime":"0","summary":"Johnson & Johnson recently announced upcoming presentations at the AUA Annual Meeting, showcasing promising developments in its oncology pipeline, particularly therapies TAR-200 and TAR-210, which could have impacted its stock by highlighting innovative advances. During the last quarter, J&J's share price moved up 5.92%, amid a broader market upswing driven by strong trading sessions like the Dow Jones' 1,000-point surge. The company’s efforts in enhancing its dividend by 4.8% and its reported earnings growth contributed additional positive sentiment, aligning with a broader market trend that has remained relatively stable over the past year, despite brief volatility.View our complete analysis and fair value estimate and you decide.NYSE:JNJ Revenue & Expenses Breakdown as at Apr 2025","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/johnson-johnson-nyse-jnj-showcases-172815984.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2592432038.USD","LU0289739699.SGD","LU2505996509.AUD","LU0345769128.USD","LU0345770308.USD","LU1059921491.USD","LU1244550577.SGD","IE00BFTCPJ56.SGD","LU1244550494.USD","LU1674673428.USD","LU1162221912.USD","NYSE","LU0345770993.USD","LU2129689431.USD","LU0466842654.USD","LU1935042991.SGD","LU1066051811.HKD","LU1221951046.USD","BK4592","LU1430594728.SGD","IE0002141913.USD","LU0122379950.USD","BK4585","IE00B7SZLL34.SGD","LU0985320562.USD","LU1674673691.USD","IE00BSNM7G36.USD","IE0009355771.USD","IE00BLSP4452.SGD","IE0034235303.USD","IE00B19Z3B42.SGD","LU1732799900.SGD","LU0058720904.USD","LU2347655156.SGD","BK4568","LU0912757837.SGD","JNJ","LU1267930813.SGD","LU0345769631.USD","LU2430703178.SGD","LU1261432733.SGD","LU2129689605.HKD","LU0203347892.USD","LU2129689514.USD","LU1894683348.USD","LU0320765646.SGD","LU1914381329.SGD","LU1066051225.USD","BK4559","LU1023059063.AUD"],"gpt_icon":0},{"id":"2529353716","title":"Stocks That Pay Almost 10% Dividend Yields: Dow and Lyondell -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2529353716","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529353716?lang=en_us&edition=fundamental","pubTime":"2025-04-23 01:18","pubTimestamp":1745342280,"startTime":"0","endTime":"0","summary":"A surprising group of companies now carry some of the highest dividend yields in the S&P 500 index.The two highest yields at nearly 10% belong to chemical firms Dow and LyondellBasell Industries.Others in the index's top 20 of biggest dividend yields include Pfizer, Franklin Resources, Invesco, United Parcel Service, and T. Rowe Price. These stocks carry yields from 6% to nearly 8%.Dow and Lyondell shares, by contrast, have been hammered in the past 12 months, with Dow stock down nearly 50% to $29, and Lyondell off about 40% to $57. Dow now yields 9.7% and Lyondell, 9.2%. \"We are dedicated to maintaining and growing our dividend and meeting our de-levering targets by the end of 2025, providing for a more balanced capital allocation,\" said Pfizer Chief Financial Officer David Denton, on the first-quarter conference call. The company's payout ratio is high at 60%, about double that of the S&P 500 index, but","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","BK4135","OEX","TROW","BK4090","IE0002270589.USD","SG9999001176.USD","LU1894683264.USD","IVV","BK4599","LU1057294990.SGD","BK4568","SG9999013999.USD","BK4534","BEN","LU0170899867.USD","LU0122379950.USD","LU0225284248.USD","LU0306806265.USD","SSO","IE00B19Z3B42.SGD","BK4007","LU0321505868.SGD","BK4567","LU1883839398.USD","LU0289739699.SGD","SDS","ESmain","DOW","IE00BLSP4452.SGD","LU0234572021.USD","BK4533","IE00BLSP4239.USD","LYB","BK4588","LU1023059063.AUD","SPXU","SG9999001176.SGD","SGXZ57979304.SGD","OEF","SG9999002232.USD","SH","LU1066051498.USD","VOO","LU0225771236.USD","SPY","BK4581",".SPX"],"gpt_icon":1},{"id":"2529589250","title":"FOCUS-Trump looking at cutting US drug prices to international levels, sources say","url":"https://stock-news.laohu8.com/highlight/detail?id=2529589250","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529589250?lang=en_us&edition=fundamental","pubTime":"2025-04-22 21:53","pubTimestamp":1745330016,"startTime":"0","endTime":"0","summary":"FOCUS-Trump looking at cutting US drug prices to international levels, sources sayGovernment health officials told source they were exploring an international reference pricing policyU.S. pays nearly three times more than other developed countries for drugsThe policy is more concerning to the pharmaceuticals industry than tariffs, sources sayAdds comparison of U.S., Swedish and Japanese prices for blood thinner Eliquis in paragraph 14By Patrick  Wingrove","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nL1N3R00GF:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1323610961.USD","LU2125154778.USD","LU0122379950.USD","LU2133065610.SGD","IE00BBT3K403.USD","SG9999011175.SGD","LU1430594728.SGD","LU0237698245.USD","LU0456855351.SGD","LU1023059063.AUD","LU1868836757.USD","LU1670710661.SGD","BK4568","SG9999013999.USD","BK4533","LU1989771016.USD","LU1718418525.SGD","IE00B19Z3B42.SGD","LU2125154935.USD","LU0882574055.USD","LU1585245621.USD","LU0321505868.SGD","LU0114720955.EUR","IE0002270589.USD","BK4007","LU1894683264.USD","LU1670711040.USD","LU1261432733.SGD","LU0225771236.USD","LU1868836914.USD","LU1883839398.USD","LU2242652126.USD","SG9999003800.SGD","IE000M9KFDE8.USD","LU0225284248.USD","BK4588","LU1093756168.USD","SGXZ57979304.SGD","LU1670710588.SGD","LU0306806265.USD","IE00B19Z3581.USD","LU2360032135.SGD","SG9999002232.USD","SG9999001176.USD","BMY","LU0058720904.USD","IE00BFXG1179.USD","LU0061475181.USD","LU1074936037.SGD"],"gpt_icon":1},{"id":"2529229581","title":"Is Gilead Sciences (GILD) a Cheap NASDAQ Stock to Buy According to Hedge Funds?","url":"https://stock-news.laohu8.com/highlight/detail?id=2529229581","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529229581?lang=en_us&edition=fundamental","pubTime":"2025-04-22 21:52","pubTimestamp":1745329942,"startTime":"0","endTime":"0","summary":"We recently published a list of the 11 Cheap NASDAQ Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Gilead Sciences, Inc.  stands against other cheap NASDAQ stocks.We first used the Finviz stock screener to compile a list of cheap NASDAQ stocks that had a forward P/E ratio under 15 as of April 21. We then selected the 11 stocks that were the most popular among elite hedge funds and that analysts were bullish on. The stocks are ranked in ascending order of the number of","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-sciences-gild-cheap-nasdaq-135222209.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z3B42.SGD","TSYW.SI","BK4578","USAW.SI","USJW.SI","BK4112","BK4550","LU0889565916.HKD","IE00B64PRP62.GBP","NQmain","GILD","LU2095319765.USD","BK4568","LU0058720904.USD",".IXIC","TQQQ","LU1839511570.USD","LU1066053197.SGD","IE00BKPKM429.USD","BK4532","IE00B7SZLL34.SGD","QLD","IE00B3T34201.USD","LU0234570918.USD","IE00B3QW5Z07.USD","LU1430594728.SGD","LU2210149790.SGD","LU2087621335.USD","NVIW.SI","BK4585","BK4566","IE00BGHQF748.EUR","SQQQ","IE00BSNM7G36.USD","LU0289739699.SGD","LU1571399168.USD","LU2210150020.SGD","QID","IE0002270589.USD","BK4139","MNQmain","LU0320765992.SGD","BK4588","NDAQ","LU1585245621.USD","PSQ","IE00BKVL7J92.USD","LU1066051498.USD","LU2468319806.SGD"],"gpt_icon":1},{"id":"2529586552","title":"Pfizer Inc. (PFE): Among Recent Activist Investor Campaigns","url":"https://stock-news.laohu8.com/highlight/detail?id=2529586552","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529586552?lang=en_us&edition=fundamental","pubTime":"2025-04-22 21:36","pubTimestamp":1745328964,"startTime":"0","endTime":"0","summary":"We recently published a list of 15 Recent Activist Investor Campaigns. In this article, we are going to take a look at where Pfizer Inc.  stands against other recent activist investor campaigns.Economic uncertainty and market volatility are some of the factors fueling activist investor campaigns in 2025. In the first quarter alone, there was a 17% jump in activist campaigns, affirming how high-profile activist investors are becoming agitated and increasingly pushing for strategic changes aimed at unlocking shareholder value.“We are in a phase where activists continue to take advantage of all the uncertainties,” said Jim Rossman, global head of shareholder advisory at Barclays. “In early 2025 we have seen more fights, more settlements and more board seats won by the activists than we did this time a year ago.”The decline came amid growing concerns that big investors will not support the measures. Additionally, ESG-focused activist investors also remained wary that Republican regulators ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-inc-pfe-among-recent-133604076.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0321505868.SGD","LU1883839398.USD","LU0306807586.USD","LU1057294990.SGD","SG9999013999.USD","SG9999001176.USD","IE000M9KFDE8.USD","LU0122379950.USD","BK4550","SG9999001176.SGD","IE00B19Z3B42.SGD","LU0985481810.HKD","BK4585","LU1066051498.USD","SG9999011175.SGD","LU0058720904.USD","IE00B19Z3581.USD","LU0170899867.USD","BK4599","SG9999002232.USD","LU0225771236.USD","IE00BLSP4452.SGD","LU0225284248.USD","LU1023059063.AUD","SG9999003800.SGD","ESG","IE0002270589.USD","BK4588","BK4533","LU1894683348.USD","IE00BBT3K403.USD","PFE","IE00BLSP4239.USD","LU0306806265.USD","BK4534","LU0868494617.USD","LU0456855351.SGD","BK4568","LU0234572021.USD","LU1894683264.USD","BK4581","BK4592","BK4007","SG9999002224.SGD","LU0289739699.SGD","LU1066053197.SGD","LU0321505439.SGD","SGXZ57979304.SGD"],"gpt_icon":1},{"id":"2529884085","title":"iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio","url":"https://stock-news.laohu8.com/highlight/detail?id=2529884085","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529884085?lang=en_us&edition=fundamental","pubTime":"2025-04-22 20:00","pubTimestamp":1745323200,"startTime":"0","endTime":"0","summary":"In-Licensing of novel activin E antibody underscores iBio’s commitment to delivering meaningful benefits to patients living with obesity and cardiometabolic diseases. “Our decision to license this Activin E-targeting functional antibody, a potentially first-in-class molecule, at this early stage reflects our firm belief in Activin E as a promising therapeutic target and our confidence in building upon the strong preclinical data we recently published,” said Martin Brenner, Ph.D., DVM, iBio’s Chief Executive Officer and Chief Scientific Officer. “This antibody represents a strategic expansion of our pipeline in cardiometabolic diseases and obesity and a significant step toward clinical development of a medi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ibio-expands-cardiometabolic-obesity-pipeline-120000559.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4568","IBIO","BK4139"],"gpt_icon":0},{"id":"2529379416","title":"FACTBOX-European companies cut jobs as economy slows","url":"https://stock-news.laohu8.com/highlight/detail?id=2529379416","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529379416?lang=en_us&edition=fundamental","pubTime":"2025-04-22 18:53","pubTimestamp":1745319231,"startTime":"0","endTime":"0","summary":"FACTBOX-European companies cut jobs as economy slowsAdds Stellantis, Volvo, Deutsche Bank, UBS, Morrisons and Nestle; changes cut-off period to March","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nL8N3R00FN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTX","BK4568","BK4585","BK4551","BK4548","BK4535","BK4588","BK4139"],"gpt_icon":0},{"id":"2529722603","title":"BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529722603","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529722603?lang=en_us&edition=fundamental","pubTime":"2025-04-22 18:45","pubTimestamp":1745318700,"startTime":"0","endTime":"0","summary":"MAINZ, Germany, April 22, 2025  --BioNTech SE  will announce its financial results for the first quarter 2025 on Monday, May 5, 2025. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT  for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be available via this link.Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page in the Investor Relations section of the Company’s website at www.BioNTech.com. A replay of the webcast will be made available shortly after the call and archived on the Company’s website for 30 days following the call.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biontech-report-first-quarter-2025-104500441.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4548","BK4230","BK4551","BK4535","BK4022","BK4585","CAR","BK4588","BK4568","BNTX"],"gpt_icon":0},{"id":"2529533378","title":"BRIEF-UK's MHRA Says Marstacimab Approved For Patients Aged 12 Years & Above With Haemophilia A Or B","url":"https://stock-news.laohu8.com/highlight/detail?id=2529533378","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529533378?lang=en_us&edition=fundamental","pubTime":"2025-04-22 18:12","pubTimestamp":1745316769,"startTime":"0","endTime":"0","summary":"BRIEF-UK's MHRA Says Marstacimab Approved For Patients Aged 12 Years & Above With Haemophilia A Or BApril 22  - UK'S MHRA: UK'S MHRA: MARSTACIMAB APPROVED TO TREAT PATIENTS AGED 12 YEARS AND ABOVE  WITH HAEMOPHILIA A OR BFurther company coverage: PFE.N ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nFWN3R00VL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BBT3K403.USD","IE00B19Z3581.USD","LU0225771236.USD","LU0321505439.SGD","SG9999002232.USD","BK4568","BK4581","BK4007","LU1894683264.USD","LU0122379950.USD","LU1883839398.USD","SG9999001176.USD","LU0306807586.USD","SG9999001176.SGD","SGXZ57979304.SGD","BK4534","BK4588","LU0234572021.USD","PFE","BK4550","LU0170899867.USD","SG9999003800.SGD","LU0058720904.USD","LU0289739699.SGD","SG9999013999.USD","IE000M9KFDE8.USD","IE00B19Z3B42.SGD","LU1023059063.AUD","BK4585","SG9999011175.SGD","LU0306806265.USD","LU1066051498.USD","LU1894683348.USD","LU0321505868.SGD","LU0225284248.USD","LU1066053197.SGD","IE00BLSP4239.USD","IE0002270589.USD","SG9999002224.SGD","LU0868494617.USD","BK4599","LU0456855351.SGD","LU0985481810.HKD","LU1057294990.SGD","BK4533","IE00BLSP4452.SGD","BK4592"],"gpt_icon":0},{"id":"2529378358","title":"UK's Mhra: Marstacimab Approved to Treat Patients Aged 12 Years and Above (Weighing at Least 35 Kg) With Haemophilia a or B","url":"https://stock-news.laohu8.com/highlight/detail?id=2529378358","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529378358?lang=en_us&edition=fundamental","pubTime":"2025-04-22 18:11","pubTimestamp":1745316669,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nFWN3R00VL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1894683264.USD","LU1894683348.USD","LU0306806265.USD","LU0170899867.USD","LU0456855351.SGD","LU0225771236.USD","LU0306807586.USD","LU0289739699.SGD","LU0321505868.SGD","LU0321505439.SGD","LU1883839398.USD","BK4568","BK4592","LU1057294990.SGD","LU1066051498.USD","IE000M9KFDE8.USD","IE00B19Z3581.USD","SG9999001176.SGD","LU0234572021.USD","LU1023059063.AUD","SG9999003800.SGD","IE00BLSP4239.USD","IE0002270589.USD","LU0985481810.HKD","BK4588","LU0058720904.USD","IE00BLSP4452.SGD","BK4007","BK4599","BK4533","PFE","LU0122379950.USD","LU0868494617.USD","SG9999002224.SGD","LU0225284248.USD","IE00B19Z3B42.SGD","SG9999002232.USD","BK4581","SG9999013999.USD","BK4550","SG9999001176.USD","BK4534","SGXZ57979304.SGD","LU1066053197.SGD","IE00BBT3K403.USD","BK4585","SG9999011175.SGD"],"gpt_icon":0},{"id":"2529340744","title":"Hutchmed Completes Patient Enrollment in Phase II Gastric Cancer Trial in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2529340744","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529340744?lang=en_us&edition=fundamental","pubTime":"2025-04-22 16:43","pubTimestamp":1745311386,"startTime":"0","endTime":"0","summary":"Hutchmed   said late Monday it completed enrollment in the registration phase of a phase II trial to assess the efficacy, safety and tolerability of savolitinib in gastric cancer patients with MET amplification.A total of 64 patients have been enrolled in the trial.If positive, the company may begin plans to apply for marketing authorization of savolitinib for gastric cancer in China later this year, it said.Savolitinib is being jointly developed by AstraZeneca  and Hutchmed, and commercialized by AstraZeneca.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0109394709.USD","BK4531","BK4585","LU2236285917.USD","BK4588","BK1587","BK4568","LU2417539215.USD","LU0320765992.SGD","00013","LU2462157665.USD","BK4007","LU0889565916.HKD","LU2456880835.USD","AZN","BK1191","LU1829250122.USD","HCM","BK1588"],"gpt_icon":0},{"id":"2529496193","title":"Goldman Sachs Remains a Buy on AstraZeneca (AZN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2529496193","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529496193?lang=en_us&edition=fundamental","pubTime":"2025-04-22 15:56","pubTimestamp":1745308606,"startTime":"0","endTime":"0","summary":"In a report released today, Rajan Sharma from Goldman Sachs maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/goldman-sachs-remains-a-buy-on-astrazeneca-azn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/goldman-sachs-remains-a-buy-on-astrazeneca-azn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4516","BK4568","LU2237443465.HKD","IE0004086264.USD","BK4588","LU1868836591.USD","LU2237443382.USD","LU1868836914.USD","LU2471134796.USD","LU1868836757.USD","BK4504","LU2237443549.SGD","LU2237443978.SGD","LU2237438978.USD","LU2456880835.USD","LU2462157665.USD","LU2750360997.AUD","LU2750360641.GBP","IE00B19Z3581.USD","BK4007","LU0251142724.SGD","LU2471134523.USD","BK4552","AZN","LU0048573561.USD","IE0002270589.USD","IE00B19Z3B42.SGD","LU1668664300.SGD","BK4533","LU2237443622.USD","BK4127","IE00BSNM7G36.USD","LU0061475181.USD","LU2471134879.HKD","LU2471134952.CNY","LU0106831901.USD","IE00BFXG1179.USD","LU0742534661.SGD","LU2236285917.USD","LU1868837300.USD","IE0034235188.USD","LU0251131958.USD","BK4550","LU2237443895.HKD","LU2417539215.USD","LU0096364046.USD","IE0004091025.USD","LU0109394709.USD","LU1829250122.USD","BK4585"],"gpt_icon":0},{"id":"2529396998","title":"EQ Resources Limited Appoints New Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2529396998","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529396998?lang=en_us&edition=fundamental","pubTime":"2025-04-22 10:47","pubTimestamp":1745290041,"startTime":"0","endTime":"0","summary":"The latest announcement is out from EQ Resources Limited ( ($AU:EQR) ). EQ Resources Limited has announced the appointment of Mr. Craig Richard Bra...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eq-resources-limited-appoints-new-director?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eq-resources-limited-appoints-new-director?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4568","EQ","BK4139"],"gpt_icon":0},{"id":"2529652773","title":"EQ Resources Strengthens Board with Industry Veteran Appointment","url":"https://stock-news.laohu8.com/highlight/detail?id=2529652773","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529652773?lang=en_us&edition=fundamental","pubTime":"2025-04-22 08:27","pubTimestamp":1745281634,"startTime":"0","endTime":"0","summary":"An update from EQ Resources Limited ( ($AU:EQR) ) is now available. EQ Resources Limited has appointed Craig Bradshaw, a veteran in the tungsten in...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eq-resources-strengthens-board-with-industry-veteran-appointment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eq-resources-strengthens-board-with-industry-veteran-appointment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4568","BK4139","EQ"],"gpt_icon":0},{"id":"2529571823","title":"Why the Market Dipped But Novavax (NVAX) Gained Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2529571823","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529571823?lang=en_us&edition=fundamental","pubTime":"2025-04-22 05:45","pubTimestamp":1745271930,"startTime":"0","endTime":"0","summary":"Novavax  closed the most recent trading day at $6.01, moving +0.17% from the previous trading session. This change outpaced the S&P 500's 2.36% loss on the day. Elsewhere, the Dow saw a downswing of 2.48%, while the tech-heavy Nasdaq depreciated by 2.55%.Prior to today's trading, shares of the vaccine maker had lost 21.05% over the past month. This has lagged the Medical sector's loss of 9.83% and the S&P 500's loss of 5.6% in that time.Analysts and investors alike will be keeping a close eye on the performance of Novavax in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $0.19, marking a 118.1% rise compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $71.84 million, down 23.47% from the year-ago period.The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our res","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-market-dipped-novavax-nvax-214530987.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","NVAX","BK4568","BK4547","BK4139","BK4588"],"gpt_icon":0},{"id":"2529356819","title":"Cassava Sciences Chief Medical Officer Kupiec Retires","url":"https://stock-news.laohu8.com/highlight/detail?id=2529356819","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529356819?lang=en_us&edition=fundamental","pubTime":"2025-04-22 05:17","pubTimestamp":1745270220,"startTime":"0","endTime":"0","summary":"Cassava Sciences said its chief medical officer, Dr. James Kupiec, is retiring, effective May 9.Under Kupiec, the clinical-stage biotechnology company completed a clinical trial program in Alzheimer's disease drug development. Kupiec has been chief medical officer since December 2022 following a stint as Cassava's chief clinical development officer. He previously worked at Pfizer.Cassava on Monday also said it appointed Jack Moore as senior vice president of clinical development. Moore was most recently the head of global medical affairs at Alector, and also worked at Janssen Pharmaceutica, Novartis Pharmaceuticals, and Celgene.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0321505439.SGD","IE00B19Z3581.USD","IE00BBT3K403.USD","BK4547","IE000M9KFDE8.USD","LU0058720904.USD","LU1023059063.AUD","SAVA","IE00B19Z3B42.SGD","SG9999013999.USD","SG9999003800.SGD","LU1894683264.USD","BK4550","LU0289739699.SGD","LU0321505868.SGD","LU0170899867.USD","SG9999002232.USD","BK4581","BK4007","LU0225284248.USD","LU0234572021.USD","BK4592","BK4534","BK4585","LU0225771236.USD","LU0306807586.USD","LU1883839398.USD","IE0002270589.USD","LU0306806265.USD","LU0456855351.SGD","SGXZ57979304.SGD","SG9999001176.USD","LU1057294990.SGD","SG9999002224.SGD","SG9999011175.SGD","IE00BLSP4452.SGD","SG9999001176.SGD","BK4599","LU0122379950.USD","IE00BLSP4239.USD","LU0985481810.HKD","BK4568","LU0868494617.USD","LU1066053197.SGD","LU1894683348.USD","LU1066051498.USD","BK4533","BK4588"],"gpt_icon":1}],"pageSize":20,"totalPage":14,"pageCount":8,"totalSize":279,"code":"91000000","status":"200"}]}}